Your browser doesn't support javascript.
loading
Outcomes in patients with high- and very high-risk localized prostate cancer treated with definitive IMRT and long-term hormone therapy.
Kawamura, Norihiko; Hayashi, Takuji; Nagahara, Akira; Nakai, Yasutomo; Nakayama, Masashi; Ikawa, Toshiki; Kanayama, Naoyuki; Morimoto, Masahiro; Konishi, Koji; Nishimura, Kazuo.
Afiliación
  • Kawamura N; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Hayashi T; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Nagahara A; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Nakai Y; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Nakayama M; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Ikawa T; Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Kanayama N; Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Morimoto M; Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Konishi K; Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Nishimura K; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
Jpn J Clin Oncol ; 54(3): 346-351, 2024 Mar 09.
Article en En | MEDLINE | ID: mdl-38146119
ABSTRACT

BACKGROUND:

The aim of this study was to evaluate the effectiveness of intensity-modulated radiation therapy in combination with long-term androgen deprivation therapy for high-risk and very high-risk localized prostate cancer while also investigating factors associated with the therapeutic effect.

METHODS:

Men who fulfilled criteria for the National Comprehensive Cancer Network high-risk or very high-risk localized prostate cancer and were treated with definitive intensity-modulated radiation therapy (74-78 Gy) of the prostate and the seminal vesicle combined with androgen deprivation therapy in our institution from 2007 to 2016 were identified (n = 197). In principle, patients received androgen deprivation therapy for 3-6 months before radiation, concurrently, and for 2 years after completion of intensity-modulated radiation therapy.

RESULTS:

The median follow-up period was 96 months. The 5-year and 10-year overall survival rates in the overall population were 96.9% and 89.3%, respectively. The 5-year and 10-year cumulative incidence rates of biochemical failure were 2.5% and 16.3% in the high-risk group, and 8.6% and 32.0% in the very high-risk group, respectively, indicating a significant difference between the two groups (P = 0.023). Grade Group 5 and younger age (cutoff 70 years old) were independent predictors of recurrence (P = 0.016 and 0.017, respectively). Patients exhibiting biochemical failure within <18 months after completion of androgen deprivation therapy displayed an increased risk of cancer-specific mortality (P = 0.039) when contrasted with those who had a longer interval to biochemical failure.

CONCLUSIONS:

Patients with the National Comprehensive Cancer Network very high-risk prostate cancer, particularly those with Grade Group 5 and younger age, showed worse outcomes following intensity-modulated radiation therapy and long-term androgen deprivation therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radioterapia de Intensidad Modulada Límite: Aged / Humans / Male Idioma: En Revista: Jpn J Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Radioterapia de Intensidad Modulada Límite: Aged / Humans / Male Idioma: En Revista: Jpn J Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: Japón